English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/187148
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Preparation of titanocene-gold compounds based on highly active gold(I)-N-heterocyclic carbene anticancer agents: Preliminary in vitro studies in renal and prostate cancer cell lines

AuthorsCurado, Natalia ; Giménez, Nora; Miachin, Kirill; Aliaga-Lavrijsen, Mélanie; Cornejo, Mike A.; Jarzecki, Andrzej A.; Contel, María
KeywordsHeterometallic compounds
N-heterocyclic carbenes
Prostate cancer
Renal cancer
Titanocene-gold
Issue Date2019
PublisherWiley-VCH
CitationChemMedChem 14(11): 1086-1095 (2019)
AbstractHeterometallic titanocene-based compounds containing gold(I)-phosphane fragments have been extremely successful against renal cancer in vitro and in vivo. The exchange of phosphane by N-heterocyclic carbene ligands to improve or modulate their pharmacological profile afforded bimetallic complexes effective against prostate cancer, but less effective against renal cancer in vitro. Herein we report the synthesis of new bimetallic Ti-Au compounds by the incorporation of two previously reported highly active gold(I)-N-heterocyclic carbene fragments derived from 4,5-diarylimidazoles. The two new compounds [(η5 -C5 H5 )2 TiMe(μ-mba)Au(NHC)] (where NHC=1,3-dibenzyl-4,5-diphenylimidazol-2-ylidene, NHC-Bn 2 a; or 1,3-diethyl-4,5-diphenylimidazol-2-ylidene, NHC-Et 2 b) with the dual linker (-OC(O)-p-C6 H4 -S-) containing both a carboxylate and a thiolate group were evaluated in vitro against renal and prostate cancer cell lines. The compounds were found to be more cytotoxic than previously described Ti-Au compounds containing non-optimized gold(I)-N-heterocyclic fragments. We present studies to evaluate their effects on cell death pathways, migration, inhibition of thioredoxin reductase (TrxR) and vascular endothelial growth factor (VEGF) in the PC3 prostate cancer cell line. The results show that the incorporation of a second metallic fragment such as titanocene into biologically active gold(I) compounds improves their pharmacological profile.
Publisher version (URL)https://doi.org/10.1002/cmdc.201800796
URIhttp://hdl.handle.net/10261/187148
DOI10.1002/cmdc.201800796
ISSN1860-7179
E-ISSN1860-7187
Appears in Collections:(ISQCH) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf59,24 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.